Dec 11, 2020
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
Dec 08, 2020
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
Nov 24, 2020
Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
Nov 19, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 09, 2020
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
Nov 09, 2020
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
Oct 28, 2020
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
Oct 09, 2020
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
Sep 18, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 16, 2020
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
Sep 03, 2020
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 19, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 18, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 15, 2020
Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
Jun 08, 2020
Arena Pharmaceuticals Announces R&D Leadership Transition
Jun 01, 2020
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
May 28, 2020
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 26, 2020
Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
May 22, 2020
Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
May 20, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)